China Lung Cancer Screening Market To Reach $1.04 Billion By 2030

China Lung Cancer Screening Market Growth & Trends

The China lung cancer screening market size is anticipated to reach USD 1.04 billion by 2030 and is projected to grow at a CAGR of 11.09% during the forecast period, according to a new report by Grand View Research, Inc. This growth trajectory is driven by several pivotal factors, notably the high incidence and mortality rates of lung cancer in China. The National Library of Medicine reports that lung cancer was the most prevalent cancer in China in 2022, with approximately 1,060,600 new cases, outpacing colorectal cancer, which had 517,100 cases.

The high burden of lung cancer underscores the critical need for effective screening solutions. Advanced screening technologies, such as low-dose computed tomography (CT) scans, have revolutionized early detection, significantly improving survival rates by identifying cancers at earlier, more treatable stages. In addition, government initiatives, including the Healthy China 2030 plan, have expanded access to screening services, especially in rural and underserved areas, enhancing early detection and treatment capabilities.

Moreover, technological advancements in screening methodologies have significantly contributed to market growth. Low-dose computed tomography (LDCT) has emerged as a key tool in early lung cancer detection, offering superior sensitivity compared to traditional imaging techniques. LDCT’s ability to detect lung cancer at an early stage has been instrumental in improving patient outcomes and reducing treatment costs. The increasing availability and affordability of advanced imaging technologies have made them more accessible to a broader population, further driving market expansion.

The market's growth is also supported by innovations in diagnostic tools, such as AI-enhanced imaging technologies, which improve the accuracy and efficiency of screenings. These advancements contribute to the broader adoption of screening programs and increased market demand. For instance, in March 2024, Alibaba Group's research division, DAMO Academy, introduced a new cancer screening tool in hospitals across China. This innovative AI-powered diagnostic tool, now operational in two hospitals in Zhejiang province, significantly accelerates the detection of various cancers. The device can analyze CT scans in under three minutes-one-third of the time required for manual examination by a physician. This advancement enhances both the speed and cost-effectiveness of cancer diagnosis, marking a significant leap forward in cancer screening technology.

 Request a free sample copy or view report summary: China Lung Cancer Screening Market Report

China Lung Cancer Screening Market Report Highlights

• Non-small cell lung cancer held the largest share of 81.29% in 2023, driven notably by the high prevalence, advancements in diagnostic technology, supportive government policies, and improvements in healthcare infrastructure

• On the basis of diagnosis, Low Dose Spiral CT (LDCT) Scan held the largest share of more than 70.0% in 2023 and it is also expected to grow at the fastest CAGR over the forecast period

• In 2023, diagnostic centers commanded the largest market share of 45.36% in the lung cancer screening sector. This dominance is attributed to their utilization of advanced imaging technologies, which provide high-resolution and accurate diagnostic capabilities

China Lung Cancer Screening Market Segmentation

Grand View Research has segmented the China lung cancer screening market based on cancer, diagnosis, end use:

China Lung Cancer Screening Cancer Outlook (Revenue, USD Million, 2018 - 2030)

• Non-small Cell Lung Cancer (NSCLC)

• Small Cell Lung Cancer (SCLC)

China Lung Cancer Screening Diagnosis Outlook (Revenue, USD Million, 2018 - 2030)

• Low Dose Spiral CT Scan

• Chest X-ray

China Lung Cancer Screening End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals and Clinics

• Diagnostic Centers

• Others

List of Key Players in the China Lung Cancer Screening Market

• Biodesix

• DELFI Diagnostics, Inc.

• GE HealthCare

• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

• Siemens Healthineers AG

• Koninklijke Philips N.V.

• CANON MEDICAL SYSTEMS CORPORATION

• Medtronic

• Shanghai United Imaging Healthcare Co., LTD

• Freenome Holdings, Inc.